Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Nuvama has maintained a ‘Hold’ rating, raising its target price from Rs 1,620 to Rs 1,651. The brokerage cited strong ...

Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates ...

The drugmaker posted a profit of Rs 1,298 crore in the quarter-ended June, according to an exchange filing on Friday.

With the stock showing a rise of 2.09%, Cipla continues to be a key player in the pharmaceutical sector, demonstrating steady financial performance and active corporate actions.

Supreme Industries Ltd., Tata Chemicals Ltd., UPL, Cipla, Lupin are among the stocks that made it to analysts' recommendation ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Cipla, the country’s third-largest drugmaker by market value, was the top gainer on the Nifty 50 on Friday, rising over 3 per ...

Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

Ciplas Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood at Rs 1,778 crore, reflecting a 4% YoY ...

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla , India's third-largest drugmaker by sales, reported a better-than-expected quarterly profit on Friday, driven by higher domestic demand for its generic respiratory drugs.